dub inhibitors market forecast

Key Highlights

• The DUB Inhibitors Market Size is anticipated to grow with a significant CAGR during the study period (2020-2040).
• The attractiveness of DUB inhibitors as a target for cancer therapies has stimulated the development of DUB inhibitors–targeting immunotherapeutic strategies. 
• The key DUB Inhibitors companies actively involved include - InSilico Medicine, Molecure, KSQ Therapeutics, Roche, Mission Therapeutics, Cothera Bioscience, Asieris Pharmaceuticals, Tango Therapeutics, and others.

DelveInsight’s “DUB Inhibitors Target Population, Competitive Landscape, and Market Forecast – 2040” report delivers an in-depth understanding of the DUB Inhibitors, historical and competitive landscape, as well as the DUB Inhibitors therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The DUB Inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM DUB Inhibitors market size from 2020 to 2040. The report also covers current DUB Inhibitors inhibitor treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s potential.

DUB Inhibitors Disease Understanding

DUB Inhibitors Overview

Deubiquitinating enzymes (DUBs) are proteases that catalyse the de-ubiquitination of protein substrates and as such offer an alternative way to regulate protein homeostasis.

DUBs belong to a relatively large family of approximately 100 enzymes; classified into seven subfamilies: ubiquitin-specific proteases (USP), ubiquitin C-terminal hydrolases (UCH), ovarian tumor proteases (OTU), Machado-Josephin domain proteases (MJD), motif interacting with ubiquitin-containing novel DUB family (MINDY), JAB1/MPN/Mov34 metalloenzymes (JAMM, the only metal-dependent DUB), and zinc finger-containing ubiquitin peptidases.

Further details related to country-based variations are provided in the report...

DUB Inhibitors Epidemiology

The DUB Inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases of selected indications for DUB Inhibitors, total eligible patient pool of selected indications, total treated cases in selected indications for DUB Inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2040.

Key Findings from Epidemiology Analysis

• As per the BreastCancer.Org, in 2025, approximately 316,950 women will be diagnosed with invasive breast cancer, with 59,080 new cases of ductal carcinoma in situ (DCIS), which is non-invasive in the US.
• As per Naing et al. (2025), Burkitt lymphoma accounts for approximately 1% to 5% of all non-Hodgkin lymphomas. Sporadic Burkitt lymphoma has an annual estimated incidence of 4 per 1 million children younger than 16 years of age, whereas the incidence is 2.5 per 1 million in adults. The average age of diagnosis in pediatric patients is 3 to 12 years of age.
• As per the Seki (2025), the prevalence of Parkinson’s disease is estimated to be approximately 100–180 individuals per 100,000 population, in Japan.

DUB Inhibitors Drug Chapters

The drug chapter of the DUB Inhibitors report provides an in-depth analysis of pipeline therapies across all stages (Phase I–III), covering clinical trial data, pharmacological profiles, collaborations and agreements, approvals and patents, as well as key advantages, limitations, and recent updates, including news and press releases.

DUB Inhibitors Marketed Drugs

The drug chapter segment of the DUB Inhibitors report encloses a detailed analysis of mid and early-stage (Phase I/II, and Phase I) pipeline drugs. It also helps to understand the DUB Inhibitors’s clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

DUB Inhibitors Emerging Drugs

MTX652: Mission Therapeutics

MTX652 is a potent and selective compound currently in Phase II designed to improve mitochondrial quality and function by enhancing mitophagy through inhibition of USP30, a deubiquitylating enzyme localised to mitochondria which is a negative regulator of mitophagy. It thereby promotes cellular health by enhancing this key mechanism, which cells use to clear dysfunctional mitochondria. MTX652 has the potential to reduce the impact of impaired mitochondria associated with Ischaemic Reperfusion Injury (IRI) in the heart and kidneys in patients who have undergone heart surgery. MTX652 has potential for expansion into Duchenne’s with key benefit on cardiomyopathy.

• In March 2024, Mission Therapeutics announced that it has raised EUR 25.2 million to progress the clinical development of its drug candidates. The financing was jointly led by Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital.
• In December 2023, Mission Therapeutics announced that the US FDA has approved its IND application for its lead asset MTX652, allowing Mission Therapeutics to proceed with its Phase II clinical trial in the US.

Sepantronium Bromide (PC-002): Cothera Bioscience

Cothera’s lead program PC-002 (also known as YM155, sepantronium bromide) currently in Phase II, is a first-in-class small molecule drug inhibitor of DUB, an enzyme family which removes ubiquitin from cellular proteins otherwise destined for degradation. With more than 50% of human cancers showing increased expression, Myc is regarded as one of the most important yet “undruggable” cancer targets. By inhibiting DUB that stabilizes the Myc protein in cancer cells, PC-002 selectively induces Myc protein degradation and cell apoptosis in Myc-dependent tumors. PC-002 may potentially target multiple cancer indications involving Myc dysregulation.

• As per company’s pipeline, the drug received Orphan Drug Desigation (ODD) and Fast Track Designation (FTD) for Diffused Large B-Cell Lymphoma (DLBCL).
• In October 2024, Cothera Bioscience announced that the US FDA has granted Fast Track Designation (FTD) to its clinical program PC-002 for the treatment of relapsed or refractory Burkitt Lymphoma.

KSQ-4279/RG6614: KSQ Therapeutics/Roche

KSQ-4279 is a first-in-class small molecule inhibitor of USP1, a protein regulating DNA damage response (DDR). USP1 was identified by KSQ’s CRISPRomics platform as an attractive cancer target with established roles in DNA damage repair processes that are distinct from PARP inhibitors and other approaches currently being tested in the clinic. The drug is currently in a Phase I/II clinical trial (NCT06237881) in patients with selected advanced solid tumors. It is a dose-escalation and expansion trial of KSQ-4279 as a monotherapy and in combination.

• In July 2023, KSQ Therapeutics entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279. Under the collaboration, Roche will assume development responsibilities for KSQ-4279, which has the potential to treat a variety of cancers.

Note: A Detailed emerging therapies assessment will be provided in the final report...

DUB Inhibitors Market Outlook

The clinical development for DUB inhibitors is rapidly gaining momentum, driven by growing recognition of the UPS as a critical regulator of protein homeostasis and a promising therapeutic target. DUBs play key roles in diverse cellular processes, and their dysregulation has been implicated in cancer, neurodegenerative disorders, and viral infections. As of 2026, the DUB inhibitor landscape remains in its early-to-mid stages, with most candidates in preclinical, Phase I development, and Phase II but the potential is substantial. 

DUB Inhibitors Inhibitor Drugs Uptake

This section focuses on the uptake rate of potential emerging DUB Inhibitors expected to be launched in the market during 2025–2040.

DUB Inhibitors Pipeline Development Activities

The DUB Inhibitors pipeline report provides insights into different therapeutic candidates in the early stages. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs under different stages is expected to generate immense opportunities for the DUB Inhibitors market growth over the forecasted period.

DUB Inhibitors Pipeline Development Activities

The DUB Inhibitors clinical trials analysis report covers information on collaborations, acquisitions and mergers, licensing, and patent details for DUB Inhibitors inhibitor therapies.

KOL Views on the DUB Inhibitors Market Report

To keep up with current and future market trends, we take Industry Experts’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on DUB Inhibitors’ evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Johns Hopkins Sidney Kimmel Cancer Center and others.

Their opinion helps understand and validate current and emerging therapy treatment patterns or DUB Inhibitors market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

DUB Inhibitors Report Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and conjoint analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

DUB Inhibitors Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the DUB Inhibitors Market Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of the DUB Inhibitors inhibitor, explaining its mechanism and emerging therapies.
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information has been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborate profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the DUB Inhibitors inhibitor market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT and conjoint analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM DUB Inhibitors inhibitor market.

DUB Inhibitors Market Report Insights

• DUB Inhibitors Inhibitor Targeted Patient Pool
• DUB Inhibitors Therapeutic Approaches
• DUB Inhibitors Inhibitor Pipeline Analysis
• DUB Inhibitors Inhibitor Market Size and Trends
• Existing and future Market Opportunity

DUB Inhibitors Inhibitor Market Report Key Strengths

• Ten-Year Forecast
• The 7MM Coverage
• Key Cross Competition
• DUB Inhibitors Drugs Uptake
• Key DUB Inhibitors Market Forecast Assumptions

DUB Inhibitors Inhibitor Market Report Assessment

• Current DUB Inhibitors Treatment Practices
• DUB Inhibitors Unmet Needs
• DUB Inhibitors Analyst Views
• DUB Inhibitors Pipeline Product Profiles
• DUB Inhibitors Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• DUB Inhibitors Market Drivers
• DUB Inhibitors Market Barriers

Key Questions Answered In The DUB Inhibitors Market Report:

• What was the DUB Inhibitors inhibitor total market size, the market size by therapies, market share (%) distribution, and what would it look like in 2040? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2040?
• What are the risks, burdens, and unmet needs of treatment with DUB Inhibitors? What will be the growth opportunities across the 7MM for the patient population of DUB Inhibitors?
• What are the key factors hampering the growth of the DUB Inhibitors inhibitor market?
• What are the indications for which recent novel therapies and technologies have been developed to overcome the limitations of existing treatments?
• What key designations have been granted to the therapies for DUB Inhibitors?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?

Reasons to buy DUB Inhibitors Market Forecast Report

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the DUB Inhibitors inhibitor Market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.